Subtype
Malignant Anorectal Neoplasm
CI-CAN-00005864Explore in graph →
452 active trials1 approved drugs6 evidence items
- NCIt
- C215225
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005864Explore in graph →
Clinical trials
1,783 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (174)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05816980 | Re-irradiation for Pelvic Recurrences in Rectal Cancer Patients(Re-RAD-I) | completed | Phase 2 | 16 | Aarhus University HospitalOTHER | 2 | Apr 18, 2023 | clinicaltrials |
| NCT05807984 | Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion | not yet recruiting | Phase 2 | 31 | Xin CaiOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT05794750 |
| Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）(AK104-IIT-13) |
| not yet recruiting |
| Phase 2 |
| 50 |
| JIN JINGOTHER |
| 0 |
| Apr 6, 2023 |
| clinicaltrials |
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03038256 | Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial(EXPLORE) | unknown | Phase 2 | 244 | Peking University People's HospitalOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT03770689 | Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer | completed | Phase 1 / Phase 2 | 19 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | Mar 21, 2023 | clinicaltrials |
| NCT02399813 | A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal | completed | Phase 2 | 36 | Advaxis, Inc.INDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT03299660 | Avelumab With Chemoradiation in Locally Advanced Rectal Cancer | completed | Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05763927 | Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT | unknown | Phase 2 | 44 | West China HospitalOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05136326 | Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer(CATARTIC) | recruiting | Phase 2 | 21 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT04177602 | Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial | terminated | Phase 1 / Phase 2 | 10 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03043729 | mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer | completed | Phase 2 | 119 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04009876 | A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer | completed | Phase 2 | 30 | Fundación de investigación HMOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05640726 | The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 7, 2022 | clinicaltrials |
| NCT05622357 | Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer | completed | Phase 2 | 51 | National Cancer Institute, EgyptOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT05359406 | A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis(Miracle-2) | unknown | Phase 2 | 51 | LI XIN-XIANGOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT05359393 | A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis(Miracle-1) | not yet recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | terminated | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05575635 | Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC | unknown | Phase 2 | 40 | Henan Provincial People's HospitalOTHER | 0 | Oct 12, 2022 | clinicaltrials |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | terminated | Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT05563922 | Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma(OP-TNT) | recruiting | Phase 2 | 56 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05300269 | SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | recruiting | Phase 2 | 73 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT02569645 | Rosuvastatin in the Treatment of Rectal Cancer | completed | Phase 2 | 45 | AHS Cancer Control AlbertaOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT03947775 | HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL | unknown | Phase 2 | 228 | University Health Network, TorontoOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT02402842 | Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma(Epitopes-HPV02) | completed | Phase 2 | 70 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT03666442 | Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer | completed | Phase 2 | 61 | West China HospitalOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03102047 | Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | completed | Phase 2 | 45 | NSABP Foundation IncNETWORK | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03957733 | Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients. | unknown | Phase 2 / Phase 3 | 338 | King Abdullah Medical CityOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03000374 | Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery(PIER) | completed | Phase 2 | 34 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT05274945 | Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer | completed | Phase 2 | 58 | Alexandria UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04167436 | Fit for Surgery. Multimodal Prehabilitation in Colorectal Cancer Patients | unknown | Phase 2 / Phase 3 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05241574 | Planned Non-operative Management for Rectal Cancer | unknown | Phase 2 | 23 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02465593 | A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer | terminated | Phase 1 / Phase 2 | 32 | PharmaEngineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT00308516 | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer | completed | Phase 2 | 66 | SCRI Development Innovations, LLCOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer | withdrawn | Phase 2 | 0 | Boehringer IngelheimINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2021 | clinicaltrials |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma(GCC 1314) | terminated | Phase 2 | 3 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04109755 | Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer(PEMREC) | recruiting | Phase 2 | 25 | University Hospital, GenevaOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04620473 | Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer | withdrawn | Phase 2 | 0 | Shanghai Minimally Invasive Surgery CenterOTHER | 0 | Sep 28, 2021 | clinicaltrials |
| NCT05055635 | Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)(ReRad III) | recruiting | Phase 2 | 55 | University of AarhusOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT02948348 | Study to Nivolumab Following Preoperative Chemoradiotherapy | unknown | Phase 1 / Phase 2 | 90 | Takayuki YoshinoOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT04989855 | Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT02864849 | Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer | completed | Phase 2 | 81 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT02393755 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT01902953 | Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC) | completed | Phase 2 | 16 | Maimonides Medical CenterOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04293419 | Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer(DUREC) | unknown | Phase 2 | 58 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Jun 21, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Apr 18, 2023source: clinicaltrials